JW Holdings Corporation (096760.KS)
KRW 3045.0
(0.0%)
KRW 3045.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 187.88 Billion KRW | 28.96% |
| 2022 | 150.83 Billion KRW | 35.57% |
| 2021 | 100.51 Billion KRW | -20.26% |
| 2020 | 80.23 Billion KRW | 197.89% |
| 2019 | 47.58 Billion KRW | -33.57% |
| 2018 | 67.89 Billion KRW | -45.13% |
| 2017 | 73.74 Billion KRW | 96.23% |
| 2016 | 66.26 Billion KRW | 10.5% |
| 2015 | 56.25 Billion KRW | 16.71% |
| 2014 | 38.51 Billion KRW | -46.6% |
| 2013 | 91.19 Billion KRW | 134.95% |
| 2012 | 36.74 Billion KRW | 1.78% |
| 2011 | 30.09 Billion KRW | -36.92% |
| 2010 | 59.95 Billion KRW | -17.57% |
| 2009 | 75.02 Billion KRW | 22.63% |
| 2008 | 67.71 Billion KRW | 246.76% |
| 2007 | 17.17 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 38.11 Billion KRW | -25.55% |
| 2024 Q1 | 51.19 Billion KRW | -14.65% |
| 2023 Q1 | 103.72 Billion KRW | 107.61% |
| 2023 Q3 | 103.19 Billion KRW | -8.41% |
| 2023 FY | - KRW | 28.96% |
| 2023 Q4 | 59.98 Billion KRW | -41.88% |
| 2023 Q2 | 112.67 Billion KRW | 8.63% |
| 2022 Q4 | 49.96 Billion KRW | 47.59% |
| 2022 Q2 | 28.11 Billion KRW | -16.75% |
| 2022 FY | - KRW | 35.57% |
| 2022 Q1 | 33.77 Billion KRW | -0.38% |
| 2022 Q3 | 33.85 Billion KRW | 20.4% |
| 2021 Q4 | 33.9 Billion KRW | 13.69% |
| 2021 FY | - KRW | -20.26% |
| 2021 Q1 | 29.3 Billion KRW | -60.0% |
| 2021 Q2 | 14.44 Billion KRW | -50.7% |
| 2021 Q3 | 29.81 Billion KRW | 106.39% |
| 2020 Q2 | 13.67 Billion KRW | 42.31% |
| 2020 Q1 | 9.61 Billion KRW | 169.59% |
| 2020 FY | - KRW | 197.89% |
| 2020 Q4 | 73.25 Billion KRW | 236.86% |
| 2020 Q3 | 21.74 Billion KRW | 58.98% |
| 2019 Q4 | -13.81 Billion KRW | -153.56% |
| 2019 Q3 | 25.78 Billion KRW | 44.64% |
| 2019 Q2 | 17.82 Billion KRW | 15.01% |
| 2019 Q1 | 15.5 Billion KRW | 4936.83% |
| 2019 FY | - KRW | -33.57% |
| 2018 Q4 | 307.78 Million KRW | -98.37% |
| 2018 Q1 | 19.79 Billion KRW | 6844.05% |
| 2018 FY | - KRW | -45.13% |
| 2018 Q2 | 28.08 Billion KRW | 41.87% |
| 2018 Q3 | 18.88 Billion KRW | -32.77% |
| 2017 Q3 | 17.13 Billion KRW | -19.57% |
| 2017 FY | - KRW | 96.23% |
| 2017 Q4 | 285.1 Million KRW | -98.34% |
| 2017 Q1 | 22.8 Billion KRW | 48.67% |
| 2017 Q2 | 21.3 Billion KRW | -6.57% |
| 2016 Q1 | 19.45 Billion KRW | 41.24% |
| 2016 Q2 | 18.14 Billion KRW | -6.71% |
| 2016 Q3 | 14.66 Billion KRW | -19.18% |
| 2016 FY | - KRW | 10.5% |
| 2016 Q4 | 15.34 Billion KRW | 4.59% |
| 2015 FY | - KRW | 16.71% |
| 2015 Q4 | 13.77 Billion KRW | 7.08% |
| 2015 Q2 | 16.69 Billion KRW | 26.89% |
| 2015 Q1 | 13.16 Billion KRW | -13.82% |
| 2015 Q3 | 12.86 Billion KRW | -22.96% |
| 2014 Q3 | 17.5 Billion KRW | 160.25% |
| 2014 Q2 | 6.72 Billion KRW | -34.85% |
| 2014 Q1 | 10.32 Billion KRW | 3.75% |
| 2014 FY | - KRW | -46.6% |
| 2014 Q4 | 15.27 Billion KRW | -12.74% |
| 2013 Q1 | 15.99 Billion KRW | 43.0% |
| 2013 Q3 | 11.75 Billion KRW | -78.22% |
| 2013 Q4 | 9.94 Billion KRW | -15.35% |
| 2013 FY | - KRW | 134.95% |
| 2013 Q2 | 53.96 Billion KRW | 237.31% |
| 2012 Q4 | 11.18 Billion KRW | -11.21% |
| 2012 Q2 | 8.27 Billion KRW | 26.1% |
| 2012 Q1 | 6.56 Billion KRW | 0.0% |
| 2012 FY | - KRW | 1.78% |
| 2012 Q3 | 12.6 Billion KRW | 52.2% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 FY | - KRW | -36.92% |
| 2011 Q2 | -2.56 Billion KRW | -135.79% |
| 2011 Q1 | 7.16 Billion KRW | 0.0% |
| 2011 Q3 | -1.38 Billion KRW | 46.08% |
| 2010 Q3 | 398.31 Million KRW | -4.64% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | - KRW | -17.57% |
| 2010 Q2 | 417.7 Million KRW | 140.06% |
| 2010 Q1 | 173.99 Million KRW | 0.0% |
| 2009 FY | - KRW | 22.63% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 795.39 Million KRW | 1830.99% |
| 2009 Q2 | 41.19 Million KRW | -96.06% |
| 2009 Q1 | 1.04 Billion KRW | 0.0% |
| 2008 FY | - KRW | 246.76% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 531.71 Million KRW | -83.5% |
| 2008 Q3 | 434.29 Million KRW | -18.32% |
| 2008 Q1 | 3.22 Billion KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 432.31 Million KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -3767.274% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | -32.909% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 393.405% |
| HANDOK Inc. | 35.06 Billion KRW | -435.794% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 18225.573% |
| Yuhan Corporation | 127.43 Billion KRW | -47.438% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -400.746% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 966.327% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 41.892% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -3664.99% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -1142.771% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -5392.153% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -4050.874% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -429.457% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -3767.274% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 1117.145% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -2766.304% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 481.169% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 466.759% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 33.756% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -110.585% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 606.882% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -1322.338% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -1488.496% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -907.166% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -3767.274% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -241.777% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | -13.93% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -110.585% |
| Yuhan Corporation | 127.43 Billion KRW | -47.438% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -461.255% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -2356.07% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -143.917% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -110.585% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -412.865% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -165.448% |
| CKD Bio Corp. | -1.63 Billion KRW | 11623.563% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -277.333% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -477.017% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -410.414% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 606.882% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -201.657% |
| Boryung Corporation | 114.28 Billion KRW | -64.396% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 714.641% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -1142.771% |
| JW Lifescience Corporation | 50.82 Billion KRW | -269.64% |